What is CNBX Pharmaceuticals Inc. (CNBX) stock price today?

CNBX Pharmaceuticals Inc. (CNBX) is currently trading at $0.00.

What is CNBX P/E ratio?

CNBX Pharmaceuticals Inc.'s P/E ratio is 0.10. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is CNBX return on equity (ROE)?

CNBX Pharmaceuticals Inc.'s return on equity (ROE) is 0.00%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is CNBX Pharmaceuticals Inc.'s market cap?

CNBX Pharmaceuticals Inc. has a market capitalization of $9251.

OTC · Biotechnology

CNBX Pharmaceuticals Inc. (CNBX) Stock

$0.00 OTC: CNBX Healthcare

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers.

Valuation

Metric	Value
Price	$0.00
Market Cap	$9251
P/E Ratio	0.10
P/B Ratio	-0.05
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	0.00%
ROA	—
ROCE	16.15%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.50
Current Ratio	0.01

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-3.0M	$-3.0M	$-1.0M	$-1.0M	$0
Net Profit	$-3.0M	$-4.0M	$-4.0M	$-1.0M	$0
EPS	$-2.16	$-3.59	$-0.42	$-0.02	$0.00
Op Margin	—	-9860.5%	-227.0%	-448.2%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$3.0M	$1.0M	$0	$0	$0
Total Liabilities	$1.0M	$2.0M	$3.0M	$3.0M	$3.0M
Cash	$1.0M	$0	$0	$0	$0
Borrowings	$1.0M	$2.0M	$1.0M	$1.0M	$1.0M

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-2.0M	$-2.0M	$0	$0	$0
Investing Cash Flow	$1.0M	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$1.0M	$-1.0M	$0	$0	$0
Free Cash Flow	$-2.0M	$-2.0M	$0	$0	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.28
FCF Yield	-1666.51%
Quick Ratio	0.00
Interest Coverage	-6.13
Return 1Y	-75.00%
Return 3Y	-99.38%
Return 5Y	—

Ownership

Insiders Held0.05%

Institutions Held6.23%

Institutions Float Held6.23%

Institutional Holder	Shares	Report Date
Archer Investment Corp	9	2024-12-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACURAcura Pharmaceuticals, Inc.	$0.00	—	0.00	$6600	0.00%
AFFYAffymax, Inc.	$0.00	—	0.00	$37490	0.00%
ENDVEndonovo Therapeutics, Inc.	$0.00	—	1.00	$31875	0.00%
FLHLFFilament Health Corp.	$0.00	—	-1.89	$26179	0.00%
GNLKQGeneLink, Inc.	$0.00	—	0.00	$10601	0.00%

About CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer. The company's development pipeline also encompasses several other potential drug candidates, including PLP-33, which targets lateral spreading or sessile colorectal polyps during colonoscopy; BRST-33, aimed at breast cancer; MLN-33, designed for melanoma; and PRST-33, intended for prostate cancer. Furthermore, CNBX is developing Cannabics SR, a lipid-based capsule containing a standardized blend of cannabinoids for managing cancer anorexia-cachexia syndrome, alongside Cannabics CDx, an ex-vivo drug sensitivity diagnostic tool. Incorporated in 2004, the company, based in Bethesda, Maryland, was formerly known as Cannabics Pharmaceuticals Inc. before officially changing its name in March 2022. It operates as a subsidiary of Cannabics Inc.

CNBX Pharmaceuticals Inc. (CNBX) stock trades at $0.00 with a market capitalization of $9251. The stock is valued at a price-to-earnings (P/E) ratio of 0.10, a negative price-to-book of -0.05, reflecting negative shareholders' equity, price-to-sales of 0.00.

On profitability, CNBX Pharmaceuticals Inc. generates a return on equity (ROE) of 0.00% (not meaningful, as shareholders' equity is negative), return on capital employed of 16.15%.

Official website: www.cnbxpharma.com